AXSM (Axsome Therapeutics) 3-Year Book Growth Rate : 9.80% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics 3-Year Book Growth Rate?

Axsome Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $1.92.

During the past 12 months, Axsome Therapeutics's average Book Value per Share Growth Rate was -66.30% per year. During the past 3 years, the average Book Value per Share Growth Rate was 9.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was 79.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Axsome Therapeutics was 137.10% per year. The lowest was -76.60% per year. And the median was 36.20% per year.

Competitive Comparison of Axsome Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Axsome Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's 3-Year Book Growth Rate falls into.

Axsome Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Axsome Therapeutics (NAS:AXSM) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Axsome Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

0HKF:UK 19X:Germany

Address

One World Trade Center, 22nd Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Executives

Mark E Saad	director	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Mark L. Jacobson	officer: Chief Operating Officer	200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
Mark Coleman	director	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Roger Jeffs	director
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Hunter R. Murdock	officer: General Counsel	22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Nick Pizzie	officer: Chief Financial Officer	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Herriot Tabuteau	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
David C Marek	officer: Chief Commercial Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski	officer: Chief Financial Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye	officer: Chief Medical Officer	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance	officer: Vice President, Finance	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc	10 percent owner	630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111